Vaccine Safety Content Methodology
How HCP Connect develops, evaluates, reviews, and maintains evidence-based vaccine safety monographs for clinicians, researchers, and the global public.
Core Editorial Framework
Vaccine-safety content is developed using authoritative sources, including the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), relevant national public-health authorities, and peer-reviewed scientific literature. Content is prepared by identified clinical authors and reviewed by qualified medical reviewers. Sources are cited within each article, and content is reviewed periodically and updated when significant changes occur in scientific evidence or official public-health recommendations.
5-Step Clinical Development & Review Lifecycle
Topic & Antigen Selection
Monographs are prioritized based on global public health schedules, WHO Strategic Advisory Group of Experts (SAGE) recommendations, CDC Advisory Committee on Immunization Practices (ACIP) schedules, and emerging vaccine safety surveillance signals.
Authoritative Evidence Retrieval
Clinical authors retrieve primary data exclusively from verified global health authorities (WHO, CDC, FDA, EMA), public health surveillance systems (VAERS, VSD, PRISM), and peer-reviewed journals indexed in MEDLINE/PubMed.
Named Clinical Authorship
Each monograph is synthesized by credentialed physicians, pediatricians, or infectious disease specialists with explicit domain expertise in clinical immunology and public health.
Independent Peer Medical Review
Before publication, an independent medical reviewer evaluates clinical framing, contraindications, adverse reaction frequencies, and source attribution. Reviewers must declare zero conflicts of interest.
Periodic & Event-Driven Review Cycle
Content is formally re-evaluated on a structured annual cycle and immediately updated whenever significant revisions occur in scientific evidence, ACIP/SAGE guidelines, or FDA product labeling.
Source Sourcing & Evidence Appraisal Framework
HCP Connect maintains a strict hierarchy of evidence to ensure all clinical safety statements, contraindication profiles, and reaction rates reflect gold-standard epidemiological data:
Tier 1: Global & National Health Authorities
WHO Position Papers & SAGE statements, CDC ACIP MMWR Recommendations, FDA Approved Package Inserts & Safety Alerts, EMA Product Information.
Application: Primary foundation for dosage, contraindications, and mandated safety protocols.
Tier 2: Peer-Reviewed Scientific Journals
The Lancet Infectious Diseases, New England Journal of Medicine (NEJM), Vaccine, Pediatrics, JAMA Network, BMJ.
Application: Clinical trial outcomes, real-world post-marketing surveillance, and immunological mechanism studies.
Tier 3: Post-Marketing Active Surveillance Systems
Vaccine Safety Datalink (VSD), Post-licensure Rapid Immunization Safety Monitoring (PRISM), WHO VigiBase.
Application: Long-term epidemiological safety signals, rare adverse event rates, and population-level surveillance.
Conflict of Interest (COI) & Commercial Independence
All clinical authors and medical reviewers contributing to the Vaccine Safety Registry are required to disclose any financial, research, or consultative affiliations with vaccine manufacturers. Reviewers with active commercial conflicts are excluded from assigning safety guidance or evaluating adverse reaction frequencies.
Update Frequency, Public Corrections & Feedback
Annual Structured Review
Every monograph undergoes mandatory annual re-evaluation against updated CDC ACIP schedules, WHO position papers, and new peer-reviewed safety signals.
Rapid Event Triaging (24h)
Immediate updates are published within 24 hours of any FDA safety communication, ACIP emergency guidance, or confirmed adverse event alert.